GnRH agonist
Goserelin
Answer
Goserelin is authorised or registered in the US, the UK, Canada, Australia, Switzerland, Brazil, Serbia, Singapore and Turkey: 9 of the 10 registers read. Highest trial phase: Phase 4 (after approval). It has 449 registered trials, 123 of them running. Brand names on the FDA label register: Zoladex.
RegulatorTrial register10 regulators' registers, read 2026-08-31 to 2026-10-03 · ClinicalTrials.gov and EU CTIS, read 2026-10-03
Not medical, legal or regulatory advice.
449 trials by status
Trial registerClinicalTrials.gov and EU CTIS · read 2026-10-03 · 65 trials have posted results
Trials first submitted per year
Trial registerClinicalTrials.gov first-submitted date, last 10 years · read 2026-10-03. 2026 is not complete. 261 trials carry no first-submitted date (EU CTIS publishes none, or the year is outside this range).
Status by jurisdiction
World map| Where | Status | Register | Read |
|---|---|---|---|
| United States | FDA-approved | FDA, openfda | 2026-10-03 |
| European Union | Not on the register | EMA, ema | 2026-08-31 |
| United Kingdom | Authorised | MHRA, uk-mhra | 2026-10-03 |
| Canada | Authorised | Health Canada, ca-dpd | 2026-10-03 |
| Australia | Registered | TGA, au-artg | 2026-10-03 |
| Switzerland | Authorised | Swissmedic, ch-swissmedic | 2026-10-03 |
| Brazil | Registado | ANVISA, br-anvisa | 2026-10-03 |
| Serbia | Authorised | ALIMS, rs-alims | 2026-09-03 |
| Singapore | Registered | HSA, sg-hsa | 2026-09-03 |
| Turkey | Ruhsatli | TITCK, tr-titck | 2026-09-03 |
An EU decision applies in the 30 territories the EU register covers: its member states, and Iceland, Liechtenstein and Norway. A dashed tile has no register read for this peptide.
Side effects
Trial registerCHANGE ALERTS
Get an email when this changes
One email when the status of Goserelin changes on the register. You confirm your address first.
REGISTERED TRIALS
Newest 10 of 449 trials
| NCT05827081 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer currently recruiting participants · register updated 2026-10-02 |
|---|---|
| NCT02115282 | Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally running, but no longer enrolling · register updated 2026-10-01 |
| NCT05161195 | Roll-over Study to Allow Continued Access to Ribociclib running, but no longer enrolling · register updated 2026-10-01 |
| NCT07460752 | Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Pr currently recruiting participants · register updated 2026-10-01 |
| 2022-501024-20-00 | CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9 no status recorded · register updated 2026-09-29 |
| 2026-525328-10-00 | A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATI no status recorded · register updated 2026-09-28 |
| NCT01723774 | PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer running, but no longer enrolling · register updated 2026-09-25 |
| NCT07287098 | A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Rec currently recruiting participants · register updated 2026-09-22 |
| NCT05003752 | Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer running, but no longer enrolling · register updated 2026-09-17 |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) currently recruiting participants · register updated 2026-09-17 |
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.